Get started
Author

Holly A. Modafferi

Observed names: H. Modafferi, Holly Johnson-Modafferi, Holly Modafferi
OpenAlex ID: A5071970655
A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2016 · Michael L. Miller, Nathan E. Fishkin, et al. · Molecular Cancer Therapeutics · 102
Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma
2018 · Robert N Booher, Grzegorz S. Nowakowski, et al. · Blood · 11
Ps991 Ca‐4948, an Irak4/flt3 Inhibitor, Shows Antileukemic Activity in Mouse Models of Flt3 Wild‐type and Flt3 Mutated Acute Myeloid Leukemia (aml)
2019 · R. Booher, M.E. S. Samson, et al. · HemaSphere · 7
Abstract 4504: Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia
2015 · Katharine C. Lai, Prerak Shah, et al. · Cancer Research · 1
Supplementary Figures S1-S5 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Table S2 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Table S1 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Table S3 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Supplementary Methods from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Table S2 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Table S3 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Table S1 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Supplementary Methods from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Data from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Data from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
2023 · Michael L. Miller, Nathan E. Fishkin, et al.
Works count: 15
Citation count: 121
H-index: 3
I10-index: 2
Year
Topic
Type